{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-311402","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2026-07-22T12:56:58+00:00","discovered_at":"2026-07-22T13:00:05.321453+00:00","generated_at":"2026-07-22T13:00:29.711608+00:00","sec_items":["1.01","2.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%","bullets":["Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).","Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.","Expected to be accretive: at least $0.05 adjusted EPS in year one, at least $0.25 in year two.","Repligen preliminary Q2 revenue growth ~12% (13% organic); BioLife preliminary Q2 revenue growth ~21% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-311402","json":"https://secwatch.observer/filing/0001193125-26-311402.json","markdown":"https://secwatch.observer/filing/0001193125-26-311402.md","text":"https://secwatch.observer/filing/0001193125-26-311402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/0001193125-26-311402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/d141685d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T13:00:29.711608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}